NEW YORK (GenomeWeb) – SomaLogic has developed a nine-protein panel for assessing the risk of adverse cardiovascular events in patients with coronary heart disease.

The company published a paper describing the panel in detail this week in the Journal of the American Medical Association and plans to launch it as a commercial test performed by  its CLIA lab this fall, Stephen Williams, senior author of the JAMA study and Somalogic's chief medical officer, told GenomeWeb.